Viatris to Sell Biosimilars Business for $3 Billion. Shares Tumble.

0
27


Viatris will sell the biosimilars business of the former Mylan to the Indian drugmaker Biocon for as much as $3.3 billion.


Dreamstime

Text size



Source link